Cargando…
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874885/ https://www.ncbi.nlm.nih.gov/pubmed/33538178 http://dx.doi.org/10.2217/fon-2020-0754 |
_version_ | 1783649679362228224 |
---|---|
author | Bersanelli, Melissa Giannarelli, Diana Leonetti, Alessandro Buti, Sebastiano Tiseo, Marcello Nouvenne, Antonio Ticinesi, Andrea Meschi, Tiziana Procopio, Giuseppe Danielli, Riccardo |
author_facet | Bersanelli, Melissa Giannarelli, Diana Leonetti, Alessandro Buti, Sebastiano Tiseo, Marcello Nouvenne, Antonio Ticinesi, Andrea Meschi, Tiziana Procopio, Giuseppe Danielli, Riccardo |
author_sort | Bersanelli, Melissa |
collection | PubMed |
description | We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no. 2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The hypothesis of an effective prophylactic approach to COVID-19 would have immediate clinical relevance, especially given the lack of curative approaches. Moreover, in the ‘COVID-19 vaccine race era’ both clinical and biological results coming from the PROTHYMOS trials could even support the rationale for future combinatorial approaches, trying to rise vaccine efficacy in frail individuals. |
format | Online Article Text |
id | pubmed-7874885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Future Medicine Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-78748852021-02-10 The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients Bersanelli, Melissa Giannarelli, Diana Leonetti, Alessandro Buti, Sebastiano Tiseo, Marcello Nouvenne, Antonio Ticinesi, Andrea Meschi, Tiziana Procopio, Giuseppe Danielli, Riccardo Future Oncol Special Report We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no. 2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The hypothesis of an effective prophylactic approach to COVID-19 would have immediate clinical relevance, especially given the lack of curative approaches. Moreover, in the ‘COVID-19 vaccine race era’ both clinical and biological results coming from the PROTHYMOS trials could even support the rationale for future combinatorial approaches, trying to rise vaccine efficacy in frail individuals. Future Medicine Ltd 2021-02-04 2020-12 /pmc/articles/PMC7874885/ /pubmed/33538178 http://dx.doi.org/10.2217/fon-2020-0754 Text en © 2021 Future Medicine Ltd This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Special Report Bersanelli, Melissa Giannarelli, Diana Leonetti, Alessandro Buti, Sebastiano Tiseo, Marcello Nouvenne, Antonio Ticinesi, Andrea Meschi, Tiziana Procopio, Giuseppe Danielli, Riccardo The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients |
title | The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients |
title_full | The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients |
title_fullStr | The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients |
title_full_unstemmed | The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients |
title_short | The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients |
title_sort | right immune-modulation at the right time: thymosin α1 for prevention of severe covid-19 in cancer patients |
topic | Special Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874885/ https://www.ncbi.nlm.nih.gov/pubmed/33538178 http://dx.doi.org/10.2217/fon-2020-0754 |
work_keys_str_mv | AT bersanellimelissa therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT giannarellidiana therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT leonettialessandro therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT butisebastiano therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT tiseomarcello therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT nouvenneantonio therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT ticinesiandrea therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT meschitiziana therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT procopiogiuseppe therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT danielliriccardo therightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT bersanellimelissa rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT giannarellidiana rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT leonettialessandro rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT butisebastiano rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT tiseomarcello rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT nouvenneantonio rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT ticinesiandrea rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT meschitiziana rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT procopiogiuseppe rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients AT danielliriccardo rightimmunemodulationattherighttimethymosina1forpreventionofseverecovid19incancerpatients |